Feds give CytoSorbents ’ blood filter a shot at $3 million
CytoSorbents (NASDAQ: CTSO) said it has won another round of funding from the U.S. government to commercialize its HemoDefend red blood cell (RBC) transfusion filter. The critical-care immunotherapy company, based in Monmouth Junction, N.J., specializes in blood purification. The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health, granted the three-year, Phase IIB Bridge Small Business Innovation Research award of up to $3 million. The HemoDefend-RBC filter is designed to improve the safety and quality of the blood supply by reducing non-infectious contaminants in packed red blood cells such as potassium, free hemoglobin, bioactive lipids, cytokines and antibodies. These contaminants can cause problematic and potentially life-threatening transfusion reactions. More than 100 million RBC units are transfused worldwide each year, and according to the American Red Cross, someone in the U.S. needs blood every 2 seconds. Get the full story on our sister site, Medical Design &Outsourcing. The post Feds give CytoSorbents’ blood filter a shot at $3 million appeared first on MassDevice.
In conclusion, MGAM2 diverges from MGAM structurally and likely functionally in placentals. MGAM2 is among>1000 human proteins with EHV regions and associated with immune response. We propose that these EHV molecules may have significant implication in cancer immunotherapy and BLBC treatment.Graphical Abstract
PMID: 30887489 [PubMed - in process]
We describe a case of an 80-year-old woman with ovarian metastasis of MCC six years after excision of a cutaneous MCC on the cheek.DiscussionTo our knowledge only three cases with ovarian metastasis of MCC have been described so far. Our case is the second with distant metastasis to the ovary spreading from a primary tumor in the skin of the head, in the other two cases the primary tumor was in the inguinal skin.ConculsionMCC is a highly aggressive cutaneous and mucosal malignancy with frequent recurrence, lymph node and distant metastases. There is no clear consensus how to treat metastatic disease.
For more information go tohttp://www.cc.nih.gov/about/news/grcurrent.htmlAir date: 4/17/2019 12:00:00 PM
Publication date: Available online 19 March 2019Source: International Journal of PharmaceuticsAuthor(s): Jafar Hajavi, Maryam hashemi, Mojtaba SankianGraphical abstract
Severe immune-related adverse events have been observed when osimrtinib was given after, but not before, immune checkpoint inhibitors in patients with advanced NSCLC.Medscape Medical News
Abstract Recent clinical studies document the power of immunotherapy in treating subsets of patients with advanced cancers. In this context and with multiple cancer immunotherapeutics already evaluated in the clinic and a large number in various stages of clinical trials, it is imperative to comprehensively examine genomics data to better comprehend the role of immunity in different cancers in predicting response to therapy and in directing appropriate therapies. The approach we chose is to scrutinize the pathways and epigenetic factors predicted to drive immune infiltration in different cancer types using publicl...
Go online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical findings and how to manage treatment-related adverse effects associated with emerging agent classes. Upon completion of this activity, partici...
Far too often, cancer patients and their doctors aren ’t aware of all the side effects that accompany new cancer therapies. Some of these new medications might cause fatigue, muscle aches, general pain and discomfort. A lack of information can lead to patients being unprepared to manage their symptoms or even cause some to delay or stop treatment all together. Historically, many clinical trials did not have a method to analyze or widely report the patient’s experience while undergoing a therapy. Researchers at UCLA and across the country are trying to change that. To help people in making better-informed ...
Conditions: Anti-cancer Cell Immunotherapy; T Cell and NK Cell Intervention: Biological: NK cell therapy Sponsors: Second Affiliated Hospital of Guangzhou Medical University; Hunan Zhaotai Yongren Medical Innovation Co. Ltd. Recruiting